p53

p53 is a tumor suppressor gene (and the protein it codes for) that acts as a cellular safety check, halting the division of damaged cells and triggering their self-destruction when DNA damage cannot be repaired. When p53 is lost or mutated, damaged cells are allowed to keep dividing, which is one of the central steps in cancer development. It is the most commonly mutated gene across human cancers.

Origin

First described in 1979 by several research groups (including David Lane, Arnold Levine, and Lloyd Old) as a 53-kilodalton protein binding the SV40 virus large T antigen. The "p" stands for protein and "53" for its apparent molecular weight on a gel. Initially mistaken for an oncogene, it was reclassified as a tumor suppressor in the late 1980s and is often called the "guardian of the genome."

Significance in Asbestos Context

In mesothelioma, the p53 pathway is frequently disrupted, sometimes by direct mutation of the TP53 gene, but more often indirectly through deletion of CDKN2A (p16/p14ARF), which normally keeps p53 active. Asbestos fibers are thought to drive cancer in part by causing chronic inflammation, oxidative DNA damage, and chromosomal breakage, exactly the kinds of injury p53 is supposed to detect and stop. When p53 function is lost, cells with asbestos-induced DNA damage continue dividing instead of dying off. Pathology and molecular reports in your medical record may mention p53, TP53, or CDKN2A status; these findings can support the diagnosis of mesothelioma (versus benign reactive tissue) and may be relevant to clinical trial eligibility and to scientific testimony about how asbestos caused your disease.

Example Sentence

The pathologist noted loss of p53 staining and CDKN2A deletion in the tumor, findings consistent with malignant mesothelioma rather than benign pleural reaction.

Related Terms

Tumor Suppressor Gene, BAP1, CDKN2A, Mesothelioma, Apoptosis, Genotoxicity

Notes

• Ask your oncologist or pathologist whether p53 (TP53) and CDKN2A testing were performed on your biopsy. These results can help confirm the diagnosis and may affect clinical trial eligibility.
• Request a copy of the full pathology and molecular pathology reports for your records and for your legal team; molecular findings can support causation testimony.
• p53 mutations occur in many cancers and are not by themselves proof of asbestos causation, but combined with fiber-burden and exposure evidence they fit the pattern of asbestos-induced mesothelioma.
• If you are considering clinical trials, some experimental therapies specifically target tumors with p53 or CDKN2A pathway loss. Ask your treating center whether you qualify.